These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17124225)

  • 1. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    Hillner BE; Smith TJ
    J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant trastuzumab for breast cancer: the other side of the coin.
    Gopalakrishnan S; Linnane J
    BMJ; 2005 Nov; 331(7526):1202-3. PubMed ID: 16293846
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
    Reed SD; Schulman KA
    Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.
    Younis T; Skedgel C
    Pharmacoeconomics; 2011 May; 29(5):361-5. PubMed ID: 21504237
    [No Abstract]   [Full Text] [Related]  

  • 6. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
    Chen W; Jiang Z; Shao Z; Sun Q; Shen K
    Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
    Norum J
    Expert Opin Pharmacother; 2006 Aug; 7(12):1617-25. PubMed ID: 16872264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.
    Grove ML
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293847
    [No Abstract]   [Full Text] [Related]  

  • 9. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
    Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
    Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant trastuzumab for breast cancer: editorial does not mention health economics of drug.
    McLaren EH
    BMJ; 2005 Nov; 331(7526):1203. PubMed ID: 16293854
    [No Abstract]   [Full Text] [Related]  

  • 13. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.
    ; Burgess EP
    N Z Med J; 2006 Jul; 119(1237):U2065; author reply U2065. PubMed ID: 16862207
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.
    McKeage K; Lyseng-Williamson KA
    Pharmacoeconomics; 2008; 26(8):699-719. PubMed ID: 18620462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How much will Herceptin really cost? The money is already there.
    Minhas R
    BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158392
    [No Abstract]   [Full Text] [Related]  

  • 18. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
    Skedgel C; Rayson D; Younis T
    Value Health; 2009; 12(5):641-8. PubMed ID: 19490562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
    de Lima Lopes G; Gluck S
    J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab for early breast cancer: evolution or revolution?
    Littlejohns P
    Lancet Oncol; 2006 Jan; 7(1):22-3. PubMed ID: 16408378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.